Pharma & Biotech Global Week in Review 10 June 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Afro-Indian anti-counterfeit legislation debate; Legislation prompts India to send delegation to Africa (Spicy IP) (Afro-IP) (Afro-IP)

Drug seizures in Frankfurt spark fears of EU-wide pattern (Intellectual Property Watch)

 
General

Broad plan on IP, innovation in developing countries approved at WHO (Intellectual Property Watch)

World Health Assembly finds way forward on pandemic flu (Intellectual Property Watch)

Off the agenda, counterfeits still draw attention at Health Assembly (Intellectual Property Watch)

Q Todd speaks at BIO International Convention (Just an Examiner)

Africa: Afro-Indian counterfeit legislation debate; India to send delegation to Africa over anti-counterfeit laws (Spicy IP) (Afro-IP) (Afro-IP)

EU: Drug seizures in Frankfurt spark fears of EU-wide pattern (Intellectual Property Watch)

US: National Academies Institute of Medicine advice to Obama on global health: open access (Intellectual Property Watch)

US bill would prohibit generics delay (Intellectual Property Watch)

US: Mylan again calls for an end to authorised generics during 180-day exclusivity period (SmartBrief) (GenericsWeb)

US: Central Institute for Experimental Animals sues Jackson Laboratory over patented mouse (Patent Librarian’s Notebook)

US: Ariad petitions en banc Federal Circuit to eliminate separate written description requirement: Ariad v Lilly (Patently-O) (Patent Docs)

US: Federal Circuit clarifies role of written description requirement in interference practice: Agilent Technologies v Affymetrix (Patent Docs) (Patently-O)

US: GSK, Tafas file petitions for rehearing in Tafas v Doll (Patent Docs) (Patent Docs) (Peter Zura’s 271 Patent Blog) (Patently-O) (Inventive Step)

US: Human Genome Sciences seeks review of BPAI decision awarding priority of invention to Immunex (now Amgen) (Patent Docs)

 
Products

Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Sandoz following Para IV challenge (Patent Docs)

Cozaar (Losartan) – Netherlands: Netherlands Patent Office grants extension to SPC for Losartan (The SPC Blog)

Cozaar (Losartan) – UK: High Court upholds IPO’s decision not to grant an extension to the term of an SPC for Losartan: In the matter of E I Du Pont Nemours & Co (The SPC Blog)

Cydectin (Moxidectin) – US: US: PhotoCure and Wyeth District Court PTE decisions appealed to the Federal Circuit; effects of the PhotoCure decision are already evident: Wyeth Holding Corp v United States (FDA Law Blog)

Fosamax (Alendronate) – US: Federal Court of Appeal upholds denial of innovator profits and refuses to grant damages for future lost market share in first case under s 8 of the PM (NOC) Regulations (Pharmacapsules @ Gowlings)

Humira (Adalimumab) – US: Abbott denied summary judgment in attempt to invalidate Centocor’s Humira patents (Patent Docs)

Metvixia (Methyl aminoevulinate) – US: PhotoCure and Wyeth District Court PTE decisions appealed to the Federal Circuit; effects of the PhotoCure decision are already evident: PhotoCure ASA v Dudas (FDA Law Blog)

Mirapex (Pramipexole) – US: Appeal concerning interplay of terminal disclaimers, restrictions and patent extensions: Boehringer Ingelheim v Barr Labs (PATracer)

Nascobal (Cyanocobalamin) – US: Par files amended complaint against Fleming & Co alleging patent and trade mark infringement and unfair competition (Patent Docs)

Nexium (Esomeprazole) – Denmark: AstraZeneca faces early generic Nexium from Sandoz in Denmark (GenericsWeb)

Omnicef (Cefdinir) – US: Are product by process claims dead?: Abbott v Sandoz (Patent Baristas) (FDA Law Blog) (Patents4Life)

Optimum GAT corn – US: BASF Plant Science files patent infringement suit against Pioneer Hi-Bred International based on its sale of Optimum GAT corn; Pioneer countersues for patent infringement and declaratory judgment of non-infringement and patent invalidity (Patent Docs)

Oracea (Doxycycline) – US: Galderma submits new QI Act 30-month stay citizen petition; a new variation on an old theme (FDA Law Blog)

Plavix (Clopidogrel) – EU: Committee for Human Medicinal Products recommends that six Plavix generics be approved (GenericsWeb)

Pulmicort (Budesonide) – US: AstraZeneca granted permanent injunction against Apotex in Pulmicort patent dispute (Patent Docs)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: